ArticleJournal of substance use and addiction treatment2026
Addiction care outcomes between insured and state opioid response grant-funded patients in a Medicaid non-expansion state.
Article in Journal of substance use and addiction treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThis study examines the impact of the State Opioid Response (SOR) grant on addiction care outcomes in uninsured patients at a longitudinal addiction and co-occurring disorder clinic (LACC).
methodsIn this retrospective cohort study, treatment engagement, substance use, and acute care utilization outcomes were compared between SOR grant-funded and traditionally insured patients receiving medications for opioid use disorder (MOUD).
resultsData from 607 patients were analyzed, with 472 in the traditional insurance group and 135 in the SOR grant-funded group. The SOR grant-funded group had more male patients (70.4% vs 48%) and higher rates of cannabis use disorder (19.3% vs 12.1%), stimulant use disorder (51.9% vs 26.3%), and HCV infection (3.7% vs 0.8%). Unadjusted data showed higher rates of MOUD adherence, opioid use, and stimulant co-use in SOR grant-funded patients. After adjusting for demographic, social, and clinical differences, care outcomes were similar between the two groups, although SOR grant-funded patients had longer general hospital admissions compared to traditionally insured patients.
conclusionThe comparable adjusted outcomes between the two groups suggest that uninsured individuals can achieve similar treatment success when access to care is provided, and after accounting for demographic, social, and clinical differences. However, the longer length of stay in hospitalized SOR grant-funded patients highlights more complex health and social challenges that require additional support beyond what the SOR grant covers. These findings underscore the need to sustain and expand funding mechanisms like the SOR grant while broadening insurance coverage to address disparities in addiction care, particularly in Medicaid non-expansion states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.